Put companies on watchlist
Eckert & Ziegler SE
ISIN: DE0005659700
WKN: 565970
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Eckert & Ziegler SE · ISIN: DE0005659700 · EQS - Company News (122 News)
Country: Germany · Primary market: Germany · EQS NID: 1970673
20 August 2024 05:00PM

Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden


EQS-News: Eckert & Ziegler SE / Key word(s): Expansion/Miscellaneous
Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden

20.08.2024 / 17:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Berlin, 20.08.2024. In the presence of the Saxon State Ministers Martin Dulig and Thomas Schmidt as well as the Mayor of Dresden Dirk Hilbert, the medical technology company Eckert & Ziegler today inaugurated its new 1,700 square meter facilities in Dresden with around 200 guests. The Dresden-Rossendorf site produces and delivers high-tech systems for the production of radiopharmaceuticals worldwide and provides services for the handling and disposal of radioactive products in cancer medicine. Eckert & Ziegler is investing up to € 50 million in the expansion of the production site. The new buildings that have now been completed are the basis for the company's further expansion and create the foundation for employement of up to 100 additional highly qualified staff in plant engineering and radiopharmacy in Saxony.

Dr. Gunnar Mann, member of the Group Executive Committee of Eckert & Ziegler SE: “The expansion of our production capacities is the answer to the rapidly growing demand for nuclear medicine compounds for cancer diagnostics and therapy. We currently have around 100 employees at our Rossendorf site, and we want to be able to double this number.”

Martin Dulig, Minister of State for Economic Affairs, Labor and Transport of the Free State of Saxony: “The new building is proof of the growing success of Eckert & Ziegler in the region, but also of the fertile conditions that this location offers. The company is now making a further contribution to ensuring that we in Saxony, especially in our state capital and in Radeberg - together with the scientific institutions and the nuclear medicine companies active here and their well over 1,000 employees - are a leading radiopharmaceutical center in Europe!”

Thomas Schmidt, Minister of State for Regional Development of the Free State of Saxony: “Dresden-Rossendorf is becoming a Silicon Valley of radiopharmacy. With the neighboring 'Helmholtz-Zentrum', a large number of available specialists, a growing number of companies and an ideal infrastructure for further investments, Saxony has a rapidly developing, highly innovative technology cluster in this field.”

Dirk Hilbert, Lord Mayor of the City of Dresden: “Our strategy is the right one. We are investing EUR 6.8 million in the expansion of the Dresden-Rossendorf commercial area in order to make such establishments possible. We are happy that an internationally leading company such as Eckert & Ziegler has chosen Dresden as the location for their expansion. In addition to the semiconductor industry, we are thus setting a further focus on cutting-edge medical and nuclear research.”

Photos of the event can be found here: https://medical.ezag.com/rossendorf-photos

About Eckert & Ziegler
With over 1,000 employees, Eckert & Ziegler SE is one of the leading providers of isotope technology components for nuclear medicine and radiotherapy. At its locations worldwide, the company offers services and products in the field of radiopharmacy, from early development to commercialization. The Eckert & Ziegler shares (ISIN DE0005659700) are listed on the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Isotope Technologies Dresden GmbH (ITD)
, a wholly owned subsidiary of Eckert & Ziegler SE based in Dresden, specializes in plant engineering for handling radioactive materials and offers tailor-made hot cell solutions to international customers in the healthcare sector, industry and research and development facilities.

Gamma-Service Recycling GmbH (GSR), a wholly owned subsidiary of Eckert & Ziegler SE based in Leipzig, specializes in handling and transporting radioactive materials in Germany and abroad.

Your contact for further inquiries:

Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, www.ezag.com

Marius Wölfges, Marketing
Phone +49 (0) 30 / 94 10 84-461, marius.woelfges@ezag.de  

Karolin Riehle, Investor Relations & PR
Phone: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de



20.08.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Eckert & Ziegler SE
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-0
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX, TecDax,
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1970673

 
End of News EQS News Service

1970673  20.08.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1970673&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Eckert & Ziegler SE
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.